Benefits
Traditional expectorant use recognized in EU herbal monographs
European regulators accept primula root and primula flower as traditional herbal medicines used as an expectorant in cough associated with a cold. This rests on at least 30 years of documented use, not on trials: the assessors found no published clinical study of either plant part as the only active ingredient.
Thyme and primula root blends compared with placebo in adults
In two placebo-controlled trials in adults with acute bronchitis (150 and 361 people), thyme plus primula root drops or tablets lowered a bronchitis symptom score or daily coughing fits more than placebo over 7 to 11 days. These were two-herb products, so the share owed to cowslip is unknown.
Thyme and primula root drops compared with an ivy leaf extract
In an open-label trial in 325 adults with acute bronchitis, symptom scores fell by similar amounts on thyme and primrose drops and on a single ivy leaf extract after 7 days; the ivy product was shown non-inferior but not superior to the blend. The study had no placebo arm and was funded by Engelhard Arzneimittel, which employed three of the authors.
Primula flower in a five-herb nose and sinus blend
Primula flower is one of five herbs in a dry extract that, in two pooled placebo-controlled trials in 589 people with acute viral rhinosinusitis, lowered a symptom score slightly more than placebo after 14 days. The blend also contains gentian, sorrel, elder flower and verbena, so the effect cannot be assigned to primula.
Tolerability of primula blends in children
Observational studies of thyme and primula root blends in children, reviewed by European regulators, reported few side effects, mainly vomiting in a handful of cases. A small study in 16 children found blood alcohol stayed far below the EU safety threshold with an alcohol-containing syrup. None of these studies had a control group.
Mucus and microbe effects of primula extracts in lab and animal studies
In rats with experimental lung inflammation, a thyme and primula tablet extract reduced inflammatory cell influx and mucus protein, and cultured airway cells made less mucin. Root extracts slowed bacterial biofilm formation in culture. These are laboratory and animal findings, not effects measured in people.
Mechanism of action
Stomach-triggered reflex on airway secretions
The usual explanation, accepted by EU assessors but not proven, is that saponins mildly irritate the stomach lining, which triggers a nerve reflex that increases watery bronchial secretion and thins mucus. The same irritation explains the stomach upset seen with high doses.
Lower surface tension of mucus
Saponins are natural detergents. Assessors note they may lower the surface tension of sputum so it is easier to cough up; in an old frog experiment a dilute primula root saponin mixture increased the beating of throat cilia, while stronger concentrations stopped it.
Less mucin production in airway models
In a manufacturer study, a thyme and primula extract given by mouth to rats reduced goblet cell numbers and the mucin protein MUC5AC after an inflammatory challenge, and lowered MUC5AC gene expression in cultured human airway cells. The share due to primula was not tested.
Antimicrobial activity of root saponins in culture
Extracts and a saponin-rich fraction of cowslip root inhibited bacteria at 0.5 to 1 mg per ml and reduced biofilm formation, most strongly for Gram-negative strains. Assessors describe such antimicrobial effects as common to saponins and never verified in people.
Clinical trials
Double-blind, randomized, placebo-controlled multicenter trial of a fixed combination of thyme fluid extract and primrose root tincture (Bronchicum Tropfen), 30 drops (1 ml) five times daily for 7 to 9 days. (Gruenwald et al. 2005, Arzneimittelforschung)
150 adult outpatients with untreated acute bronchitis of less than 48 hours (75 blend, 75 placebo).
The Bronchitis Severity Score fell from 12.0 to 1.0 points on the blend and from 11.7 to 6.5 on placebo, a 5.8-point difference (p of 0.001 or less). At study end 58.7% versus 5.3% were symptom free. Adverse events: 2 on the blend, 5 on placebo. This tested a two-herb product, so the result cannot be attributed to cowslip alone.
Double-blind, placebo-controlled multicenter Phase IV trial of film-coated tablets combining dry extracts of thyme herb and primrose root (Bronchipret TP), 1 tablet three times daily for 11 days. (Kemmerich 2007, Arzneimittelforschung)
361 adult outpatients with acute bronchitis, at least 10 daytime coughing fits and a symptom score of 5 or more (183 blend, 178 placebo).
Daytime coughing fits on days 7 to 9 fell 67.1% from baseline on the blend versus 51.3% on placebo (p < 0.0001), and a 50% reduction came about 2 days sooner. Symptom score responder rates were 77.5% versus 60.1% at day 4 and 92.9% versus 75.8% at day 10. Adverse events did not differ. The effect belongs to the two-herb tablet, not cowslip alone.
Single-blind, randomized, two-center non-inferiority trial comparing a thyme fluid extract plus primrose root fluid extract (Bronchicum Elixir S, 5 ml six times daily) with thyme fluid extract plus primrose root tincture drops (1 ml five times daily) for 7 to 9 days. (Gruenwald et al. 2006, Arzneimittelforschung)
189 adult outpatients with untreated acute bronchitis of less than 48 hours (94 fluid, 95 drops).
The Bronchitis Severity Score fell by 76% with the fluid and 77.1% with the drops, with no difference between groups; about 52 to 54% were symptom free at the end. 71 patients were excluded from the per-protocol set. With no placebo arm, the trial shows only that two versions of the same blend performed alike.
Three-arm, open-label, randomized trial at ten German sites, funded by Engelhard Arzneimittel, which employed three authors; the thyme and primrose arm took Bronchicum drops, 35 drops five times daily (2.2 g thyme liquid extract and 1.1 g primrose root tincture a day) for 7 days. (Kardos et al. 2025, Pharmaceuticals (Basel))
325 adults with acute bronchitis in the analysis set; 95 were randomized to the thyme and primrose drops.
Mean symptom score change by day 7 was 8.59 points on thyme and primrose versus 9.11 on ivy extract alone (per-protocol). The ivy extract met non-inferiority, but its superiority over thyme and primrose missed significance (p < 0.0607). Nine adverse events occurred in the thyme and primrose group, including throat irritation judged drug-related; none were serious. No placebo arm, and the thyme and primrose drops were a two-herb blend, so the trial gives no estimate for cowslip alone.
Uncontrolled Phase IV study of a thyme herb and primrose root fluid extract syrup containing 4.9% ethanol (Bronchicum Elixir) taken for 7 to 9 days; authors included staff of Cassella-med GmbH. (Ludwig et al. 2016, Drug Res (Stuttg))
16 children aged 1 to 12 years with acute bronchitis of 48 hours or less.
All blood ethanol levels measured 45 and 90 minutes after a dose were below the 0.125 per mille single-dose threshold recommended by the EMA (mean 0.0029 per mille at 45 minutes). The symptom score fell from 6.6 to 0.9 points, but with no control group this does not show the syrup caused the improvement. It tested a two-herb syrup, not cowslip alone.
Pooled analysis of two randomized, double-blind, placebo-controlled trials (ARhiSi-1 and ARhiSi-2) of BNO 1016, a dry extract of gentian root, primula flower, sorrel herb, elder flower and verbena herb (1:3:3:3:3), 160 mg three times daily for 15 days. One author was employed by the maker, Bionorica, and two were its consultants. (Jund et al. 2015, Acta Otolaryngol)
589 patients with acute viral rhinosinusitis (294 BNO 1016, 295 placebo).
The major symptom score fell from about 10.0 to 2.47 on the extract and from 9.87 to 3.63 on placebo, a difference of about 1.2 points at day 14 (p < 0.0001), just above the 1-point difference set as clinically relevant. Responders at day 14 were 93.2% versus 85.1%. No serious adverse events. Primula flower is one of five herbs, so its contribution is unknown.